[go: up one dir, main page]

PE50994A1 - Derivado de 1,5 benzodiazepina - Google Patents

Derivado de 1,5 benzodiazepina

Info

Publication number
PE50994A1
PE50994A1 PE1994240027A PE24002794A PE50994A1 PE 50994 A1 PE50994 A1 PE 50994A1 PE 1994240027 A PE1994240027 A PE 1994240027A PE 24002794 A PE24002794 A PE 24002794A PE 50994 A1 PE50994 A1 PE 50994A1
Authority
PE
Peru
Prior art keywords
phenyl
alkyl
gastral
cck
halogens
Prior art date
Application number
PE1994240027A
Other languages
English (en)
Inventor
Pritom Shah
Carr Robin Arthur Ellis
Harry Finch
Original Assignee
Glaxo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Inc filed Critical Glaxo Inc
Publication of PE50994A1 publication Critical patent/PE50994A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE: 1) NR1R2 ES UN ANILLO HETEROCICLICO SATURADO DE 5 A 7 MIEMBROS QUE PUEDE ESTAR SUSTITUIDO POR 1 o 2 METILOS, TAL COMO UN ANILLO PIRROLIDINO, PIPERIDINO; 2) R3 ES UN ALQUILO C1-C6, CICLOALQUILO C3-C6, FENILO, FENILO SUSTITUIDO CON 2 HALOGENOS; 3) R4 ES UN FENILO O FENILO SUSTITUIDO CON 1 o 2 HALOGENOS, ALQUILO C1-C4, TRIFLUOROMETILO, TRIFLUOROMETOXI, (CH2)nR5 DONDE n ES 0 o 1 Y R5 ES UN ALCOXI C1-C4, Y OTROS; 4) X ES H, ALQUILO C1-C4, HALOGENO; 5) m VARIA DE 0 A 2; ESTE COMPUESTO PUEDE SER ANTAGONISTA DE LA GASTRINA Y COLECISTOCININA (CCK) TENIENDO MAYOR AFINIDAD POR EL RECEPTOR CCK-B, SIENDO UTIL EN EL TRATAMIENTO DE TRANSTORNOS GASTROINTESTINALES YA QUE PUEDE DISMINUIR LA SECRECION GASTRICA, Y EN TRANSTORNOS DEL SISTEMA NERVIOSO CENTRAL TAL COMO ANSIEDAD, DEPRESION, DISQUINESIA TARDIA
PE1994240027A 1993-04-15 1994-04-13 Derivado de 1,5 benzodiazepina PE50994A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939307833A GB9307833D0 (en) 1993-04-15 1993-04-15 Modulators of cholecystokinin and gastrin

Publications (1)

Publication Number Publication Date
PE50994A1 true PE50994A1 (es) 1995-01-06

Family

ID=10733915

Family Applications (2)

Application Number Title Priority Date Filing Date
PE1994240027A PE50994A1 (es) 1993-04-15 1994-04-13 Derivado de 1,5 benzodiazepina
PE1994240028A PE50594A1 (es) 1993-04-15 1994-04-13 Derivados 3-amido-1,5- benzodiacepina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE1994240028A PE50594A1 (es) 1993-04-15 1994-04-13 Derivados 3-amido-1,5- benzodiacepina

Country Status (33)

Country Link
US (2) US5646140A (es)
EP (1) EP0694039B1 (es)
JP (1) JP3406317B2 (es)
KR (1) KR100364948B1 (es)
CN (1) CN1058487C (es)
AP (2) AP462A (es)
AT (1) ATE198894T1 (es)
AU (1) AU681139B2 (es)
CA (1) CA2158973C (es)
CZ (1) CZ286695B6 (es)
DE (1) DE69426624T2 (es)
DK (1) DK0694039T3 (es)
EC (1) ECSP941066A (es)
ES (1) ES2154674T3 (es)
FI (1) FI954853A7 (es)
GB (1) GB9307833D0 (es)
GR (1) GR3035641T3 (es)
HU (1) HU223467B1 (es)
IL (2) IL109316A (es)
IS (2) IS4147A (es)
MY (2) MY131569A (es)
NO (1) NO311133B1 (es)
NZ (1) NZ265272A (es)
OA (1) OA10355A (es)
PE (2) PE50994A1 (es)
PH (1) PH30897A (es)
PL (1) PL178790B1 (es)
PT (1) PT694039E (es)
RU (1) RU2135486C1 (es)
SK (1) SK281211B6 (es)
TW (1) TW487703B (es)
WO (1) WO1994024149A1 (es)
ZA (2) ZA942571B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3621416B2 (ja) * 1993-12-28 2005-02-16 塩野義製薬株式会社 新規なベンゾジアゼピン誘導体
US5739129A (en) * 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
AU697349B2 (en) * 1994-04-14 1998-10-01 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1,5-benzodiazepines
PE27497A1 (es) * 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
EP0755394A1 (en) * 1994-04-15 1997-01-29 Glaxo Wellcome Inc. A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds
GB9420747D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc 1,5 benzodiazepine derivatives
GB9420763D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
US5780464A (en) * 1994-10-14 1998-07-14 Glaxo Wellcome Inc. Enteric coated compositions of 1,5-benzodiazepine derivatives having CCK antagonistic or agonistic activity
GB9420748D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc 1,5 benzodiazepine derivatives
US5910495A (en) * 1994-10-14 1999-06-08 Glaxo Wellcome Inc. Use of 1,5-benzo b!1,4-diazepines to control gastric emptying
US5750353A (en) * 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
EP0869975B1 (en) 1995-12-11 2007-08-15 New England Medical Center Hospitals, Inc. Assay for and uses of peptide hormone receptor ligands
US6239131B1 (en) * 1996-12-10 2001-05-29 Zeria Pharmaceutical Co., Ltd. 1,5 Benzodiazepine derivatives
BR9808593A (pt) 1997-04-15 2000-05-23 Csir Composições farmacêuticas com atividade supressora do apetite
AR022044A1 (es) * 1999-05-06 2002-09-04 Glaxo Group Ltd Derivados de 1,5-benzodiazepina
GB2355657B (en) 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
US20020180095A1 (en) * 2001-05-29 2002-12-05 Berard Steven O. Thermally conductive carbon fiber extrusion compounder and method of using same
CA2476936A1 (en) * 2002-02-20 2003-08-28 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
RU2261246C1 (ru) * 2004-04-15 2005-09-27 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Замещенные 7-сульфонил бензо[b][1,4]диазепины (варианты), способы их получения (варианты), фокусированная библиотека и фармацевтическая композиция
CA2568056A1 (en) * 2004-05-25 2005-12-08 Pfizer Products Inc. Tetraazabenzo[e]azulene derivatives and analogs thereof
CN1333077C (zh) * 2005-04-15 2007-08-22 华南农业大学 缩胆囊素活性片段的串联表达及其应用
RU2303597C1 (ru) * 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
ATE553093T1 (de) * 2006-08-25 2012-04-15 Abbott Lab Indazolderivate zur hemmung von trpv1 und verwendungen davon
CN101563318A (zh) * 2006-12-20 2009-10-21 艾博特公司 作为trpv1香草素受体拮抗剂用于治疗疼痛的n-(5,6,7,8-四氢萘-1-基)脲衍生物以及相关化合物
CA2719018A1 (en) * 2008-03-20 2009-09-24 Abbott Laboratories Methods for making central nervous system agents that are trpv1 antagonists
CN103102285B (zh) * 2013-01-30 2015-07-29 淮阴师范学院 对氨基苯乙腈的制备方法
DK3071203T3 (da) 2013-11-18 2021-03-15 Forma Therapeutics Inc Tetrahydroquinolinsammensætninger som bet-bromdomæne-inhibitorer
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
CN108200760B (zh) 2015-07-22 2022-04-01 英安塔制药有限公司 作为rsv抑制剂的苯并二氮杂䓬衍生物
EA201891620A1 (ru) 2016-02-05 2019-02-28 Денали Терапьютикс Инк. Ингибиторы взаимодействующей с рецептором протеинкиназы 1
PL3552017T3 (pl) 2016-12-09 2022-08-08 Denali Therapeutics Inc. Związki użyteczne jako inhibitory RIPK1
EP3582784B1 (en) 2017-02-16 2022-06-08 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
US10752598B2 (en) * 2017-06-07 2020-08-25 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as RSV inhibitors
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
AU2018339068B2 (en) 2017-09-29 2022-12-15 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as RSV inhibitors
US10647711B2 (en) 2017-11-13 2020-05-12 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as RSV inhibitors
WO2019199908A1 (en) 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
PH12021552201A1 (en) 2019-03-18 2022-05-30 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
US11179400B2 (en) 2019-04-09 2021-11-23 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
MX2024008648A (es) 2022-01-12 2024-09-23 Denali Therapeutics Inc Formas cristalinas de (s)-5-bencil-n-(5-metil-4-oxo-2,3,4,5-tetrah idropirido [3,2- b][1,4]oxacepin-3-il)-4h-1,2,4-triazol-3-carboxam ida.
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
US12162857B2 (en) 2022-04-27 2024-12-10 Enanta Pharmaceuticals, Inc. Antiviral compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517195A (en) * 1984-07-02 1985-05-14 Hoechst-Roussel Pharmaceuticals Inc. Pyrrolo[1,2-b][1,2,5]triazepines and pharmaceutical compositions thereof
FR2641280B1 (fr) * 1988-12-29 1994-01-21 Roussel Uclaf Nouveaux derives de la 2,4-dioxo 2,3,4,5-tetrahydro 1h-1,5-benzodiazepine, leur procede de preparation et leur application comme medicaments
SU1362732A1 (ru) * 1986-04-16 1987-12-30 Ленинградский Технологический Институт Им.Ленсовета Способ получени 2-диалкиламино-4-метил-3н-1,5-бензодиазепинов
CH673947A5 (es) * 1986-09-23 1990-04-30 Sandoz Ag
FR2659653B1 (fr) * 1990-03-13 1992-05-22 Rhone Poulenc Sante Derives de l'uree, leur preparation et les medicaments les contenant.
US5206234A (en) * 1990-10-22 1993-04-27 Merck & Co., Inc. Benzolactam analogs as antagonists of cck
JP2904941B2 (ja) * 1991-01-28 1999-06-14 出光興産株式会社 スチレン系重合体の精製方法
GB9201180D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
AU697349B2 (en) * 1994-04-14 1998-10-01 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1,5-benzodiazepines

Also Published As

Publication number Publication date
DE69426624T2 (de) 2001-06-21
AP462A (en) 1996-02-19
EP0694039B1 (en) 2001-01-24
DK0694039T3 (da) 2001-05-21
NO311133B1 (no) 2001-10-15
GB9307833D0 (en) 1993-06-02
JP3406317B2 (ja) 2003-05-12
DE69426624D1 (de) 2001-03-01
US5646140A (en) 1997-07-08
HK1003943A1 (en) 1998-11-13
CA2158973C (en) 2006-06-06
PL178790B1 (pl) 2000-06-30
SK281211B6 (sk) 2001-01-18
PE50594A1 (es) 1995-01-06
MY131569A (en) 2007-08-30
ZA942570B (en) 1994-11-11
ECSP941066A (es) 1994-11-16
IL109315A0 (en) 1994-07-31
NZ265272A (en) 1997-07-27
TW487703B (en) 2002-05-21
IL109316A0 (en) 1994-07-31
SK125395A3 (en) 1996-06-05
ES2154674T3 (es) 2001-04-16
OA10355A (en) 2001-10-19
NO954090D0 (no) 1995-10-13
IL109316A (en) 1999-03-12
GR3035641T3 (en) 2001-06-29
HU9502978D0 (en) 1995-12-28
AU6567694A (en) 1994-11-08
WO1994024149A1 (en) 1994-10-27
ATE198894T1 (de) 2001-02-15
HUT74102A (en) 1996-11-28
AP9400635A0 (en) 1994-04-30
KR100364948B1 (ko) 2003-03-29
IS4148A (is) 1994-10-16
CZ286695B6 (en) 2000-06-14
CZ267595A3 (en) 1996-04-17
ZA942571B (en) 1994-11-11
MY112237A (en) 2001-05-31
RU2135486C1 (ru) 1999-08-27
US5585376A (en) 1996-12-17
NO954090L (no) 1995-12-13
CN1058487C (zh) 2000-11-15
FI954853A0 (fi) 1995-10-12
PT694039E (pt) 2001-06-29
FI954853L (fi) 1995-10-12
IS4147A (is) 1994-10-16
CN1120843A (zh) 1996-04-17
JPH08508744A (ja) 1996-09-17
PL311084A1 (en) 1996-02-05
PH30897A (en) 1997-12-23
CA2158973A1 (en) 1994-10-27
AP512A (en) 1996-07-29
FI954853A7 (fi) 1995-10-12
EP0694039A1 (en) 1996-01-31
AP9400634A0 (en) 1994-04-30
HU223467B1 (hu) 2004-07-28
AU681139B2 (en) 1997-08-21

Similar Documents

Publication Publication Date Title
PE50994A1 (es) Derivado de 1,5 benzodiazepina
DE69632548D1 (de) ISOXAZOLIN, ISOTHIAZOLIN UND PYRAZOLIN ALS FAKTOR Xa INHIBITOREN
ES2106855T3 (es) Analogos de 3-benciliden-1-carbamoil-2-pirrolidona.
PE14995A1 (es) Derivado de benzofurano
DE69327541D1 (en) 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
ES2062319T3 (es) 3-(1,2,5,6-tetrahidropiridil) pirrolopiridinas.
CO5261589A1 (es) Compuestos heterociclicos, su produccion y su utilizacion
ES2111896T3 (es) Aminocompuestos sustituidos, su preparacion y metodos de tratamiento.
MX9205242A (es) Compuestos heterociclicos que contienen nitrogeno triciclico fusionado.
LV11617A (lv) Morfolins un tiomorfolins ar tahikinina receptoru antagonistu ipasibam
ES2125056T3 (es) Compuestos heteroespiranicos y su uso como materiales electroluminiscentes.
PE17895A1 (es) Antagonista triciclico diacepinico de vasopresina y antagonista de oxitocina
PE20040720A1 (es) Derivados de benzodioxol
DK0589924T3 (da) Fluoralkoxybenzylaminoderivater af nitrogenholdige heterocyclusser
ES2062974T3 (es) Compuestos de cefalosporina, procedimientos para su preparacion y agentes antibacterianos.
PE45095A1 (es) Nuevos compuestos heterociclicos
DK0561941T3 (da) N-Substituerede lactamer anvendelige som cholecystokinin-antagonister
ES2093399T3 (es) Nuevos derivados de acido fosfono-succinico, procedimiento para su preparacion y medicamentos que contienen estos compuestos.
MXPA04004501A (es) Derivados de 4-4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o sales de los mismos.
NO911158L (no) Hydantoinderivater.
PE20020144A1 (es) Derivados de pleuromutilinas como agentes antibacterianos
ATE165972T1 (de) 2(5h)- in position 3-substituierte furanone als ca 2+ antagonisten und entzündungshemmende mittel
DE69626981D1 (de) N-(2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl)-3-amide
DK0619806T3 (da) Fremstilling af substituerede piperidiner
PE8295A1 (es) Derivado de 1,5 benzodiazepina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed